Get the Stockscreener App
2.91
2.11%
0.06
Pre-market:
2.95
0.04
+1.37%
Spero Therapeutics Inc stock is traded at $2.91, with a volume of 932.50K.
It is up +2.11% in the last 24 hours and up +4.30% over the past month.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$2.85
Open:
$2.93
24h Volume:
932.50K
Relative Volume:
1.62
Market Cap:
$168.49M
Revenue:
$54.77M
Net Income/Loss:
$15.24M
P/E Ratio:
11.95
EPS:
0.2436
Net Cash Flow:
$7.24M
1W Performance:
+6.20%
1M Performance:
+4.30%
6M Performance:
+27.07%
1Y Performance:
+2.83%
1-Day Range:
$2.85
$2.966
1-Week Range:
$2.48
$2.966
52-Week Range:
$1.80
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Name
Spero Therapeutics Inc
Sector
Industry
Phone
857-242-1600
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.91 | 168.49M | 54.77M | 15.24M | 7.24M | 0.2436 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-23-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-01-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Initiated | Evercore ISI | Outperform |
| Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-19 | Initiated | Janney | Buy |
| Feb-09-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-27-17 | Initiated | BofA/Merrill | Neutral |
| Nov-27-17 | Initiated | Oppenheimer | Outperform |
| Nov-27-17 | Initiated | Stifel | Buy |
View All
Spero Therapeutics Inc Stock (SPRO) Latest News
Spero Therapeutics Stock (US85208T1079): Quiet session keeps focus on fundamentals and pipeline - AD HOC NEWS
SPRO News | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold) - Seeking Alpha
Spero Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls Amid Lack of Revenue - newsline.com
MSN Money - MSN
Spero Therapeutics (SPRO) Slips 2.41% as Stock Tests Key Support at $2.69Dark Pool Volume - newsline.com
Spero Therapeutics (SPRO) Hovers Near Support Amid Modest Decline – Key Levels in FocusCorrective Wave - The Legal Advocate
Spero Therapeutics (SPRO) Jumps 4.9% as Stock Approaches Key Resistance at $3.15Oversold Bounce Ideas - The Legal Advocate
SPRO Technical Analysis | Trend, Signals & Chart Patterns | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics (SPRO) Q1 2026 Earnings: Why the Beat MattersCEO Earnings Statement - Newser
Spero Therapeutics, Inc. Common Stock (SPRO) Stock Price Today & Analysis - Gotrade
Promising Penny Stocks To Consider In May 2026 - simplywall.st
Is Spero Therapeutics (SPRO) 110.3% Overvalued After Q1 2026 Ear - GuruFocus
Spero Therapeutics 1Q Loss $7.2M >SPRO - Moomoo
Spero Therapeutics Q1 revenue drops on decreased clinical activity - TradingView
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update - The Manila Times
Spero Therapeutics (NASDAQ: SPRO) leans on GSK-partnered tebipenem ahead June 2026 FDA date - Stock Titan
Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Spero Therapeutics (SPRO) trims Q1 2026 loss ahead key tebipenem FDA date - Stock Titan
TradingKey - TradingKey
Number of shareholders of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
SPRO SEC FilingsSpero Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
SPRO FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 25 Deadline in Securities Class ActionSPRO - TMX Newsfile
Spero Therapeutics CEO sells $63,352 in company stock By Investing.com - Investing.com Australia
Spero Therapeutics (SPRO) officer sells shares for RSU tax obligations - Stock Titan
Spero Therapeutics CEO sells $63,352 in company stock - Investing.com India
SPRO: The fleeting Sparrow - Moomoo
No call planned as Spero sets May 13 for Q1 results update - Stock Titan
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - GlobeNewswire
SPRO Stock Price, Quote & Chart | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short Interest - MarketBeat
Best Momentum Stock to Buy for October 10th - MSN
Spero Therapeutics (NASDAQ: SPRO) 2026 proxy adds stock increase and new incentive plan - Stock Titan
Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN
[ARS] Spero Therapeutics, Inc. SEC Filing - Stock Titan
ROSEN, Top Ranked Investor Counsel, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionSPRO - TMX Newsfile
Spero Therapeutics (SPRO) Stock Volume Spike Alert (Builds on Momentum) 2026-04-20Open Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
Spero Therapeutics (SPRO) Stock Insider Buying (Market Focus) 2026-04-18Algo Picks - Cổng thông tin điện tử tỉnh Lào Cai
SPRO Forecast, Price Target & Analyst Ratings | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics Stock Rises Above 50-Day Moving Average - National Today
Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
Spero Therapeutics Inc Stock (SPRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):